VolitionRX Limited
VNRX
Positions held
Your positionsVNRX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $6.60M | Enterprise value | $10.24M | Trailing P/E | — | Forward P/E | -0.26 |
| PEG | — | Price / book | -0.08 | Beta | 1.17 | Dividend yield | 0.00% |
| Revenue growth | -2.0% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -10.4% |
| Profit margin | 0.0% | ROE | — | ROA | -142.9% | Debt / equity | — |
| Current ratio | 0.30 | Free cash flow | -$9.21M | Analyst recommendation | none | Mean target | $13.62 |
| 52w high | $10.40 | 52w low | $0.22 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.4M | $1.0M | $0.4M | $0.6M | $0.4M | — |
| Op margin | -1054.0% | -530.8% | -1058.4% | -776.2% | -1529.9% | — |
| Net income | -$7.3M | -$6.7M | -$6.3M | -$5.4M | -$6.3M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$4.2M | -$5.2M | -$4.7M | -$4.9M | -$6.2M | — |
- Revenue -60% vs prior quarter ($0.4M vs $1.0M).
- Operating margin compressed to -1054%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.7M | $1.2M | $0.8M | $0.3M | — |
| Op margin | -1228.6% | -2182.5% | -4614.1% | -9971.1% | — |
| Net income | -$23.4M | -$27.0M | -$35.3M | -$30.3M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$21.2M | -$26.9M | -$35.8M | -$30.6M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-17 · VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
2026-09-17 · VolitionRx Participates in Launch of DETECSEPS Program in France
2026-09-10 · Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
2026-08-27 · Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations
2026-08-26 · VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
2026-08-26 · Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis
2026-08-20 · Volition (VNRX) Q2 2026 Earnings Call Transcript
2026-08-14 · VolitionRx Limited Q2 2026 Earnings Call Summary
2026-08-13 · VolitionRX: Q2 Earnings Snapshot
2026-08-13 · VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
Price (daily)
Full chart · RSI · MACD · patterns